NetworkNewsBreaks – Lexaria Bioscience Corp. (CS
Post# of 721
(Total Views: 281)
Posted On: 02/21/2019 3:08:27 PM
NetworkNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Releases Additional Significant Findings of its DehydraTECH(TM) Powered TurboCBD(TM) Capsules
Biotechnology company and drug delivery platform innovator Lexaria Bioscience (CSE: LXX) (OTCQX: LXRP) today announced additional significant findings of TurboCBD(TM), the company’s proprietary, DehydraTECH(TM) powered, cannabidiol (”CBD”) fortified hemp-oil capsule upon completion of further data analyses from its 2018 randomized, placebo-controlled, double-blinded European human clinical study. According to the update, a single 90mg dose of TurboCBD as compared to the same dose of generic CBD provided evidence of lower blood pressure, higher blood flow to the brain, faster delivery onset and larger quantities of CBD into the bloodstream. The study revealed key metabolic and hemodynamic performance findings linked to bioavailability enhancements. “The findings that Lexaria’s DehydraTECH(TM) technology can enable superior cannabinoid delivery are unique in this healthy-human clinical trial. However, the findings that the technology can proffer a positive influence on blood pressure and perfusion to the brain are truly remarkable,” Principal Investigator and Co-Director of the Centre for Heart, Lung and Vascular Health, UBC Okanagan Campus, Kelowna, Canada Professor Philip Ainslie, Ph.D. stated in the news release. “The potential benefits of this approach, but over the acute and more chronic time periods, in more middle-aged or elderly populations should now be prioritized. Establishing the impact of CBD delivery on the health of the circulatory systems, including the brain, could have major implications for the adjunct treatment of high blood pressure and some neurological diseases.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Biotechnology company and drug delivery platform innovator Lexaria Bioscience (CSE: LXX) (OTCQX: LXRP) today announced additional significant findings of TurboCBD(TM), the company’s proprietary, DehydraTECH(TM) powered, cannabidiol (”CBD”) fortified hemp-oil capsule upon completion of further data analyses from its 2018 randomized, placebo-controlled, double-blinded European human clinical study. According to the update, a single 90mg dose of TurboCBD as compared to the same dose of generic CBD provided evidence of lower blood pressure, higher blood flow to the brain, faster delivery onset and larger quantities of CBD into the bloodstream. The study revealed key metabolic and hemodynamic performance findings linked to bioavailability enhancements. “The findings that Lexaria’s DehydraTECH(TM) technology can enable superior cannabinoid delivery are unique in this healthy-human clinical trial. However, the findings that the technology can proffer a positive influence on blood pressure and perfusion to the brain are truly remarkable,” Principal Investigator and Co-Director of the Centre for Heart, Lung and Vascular Health, UBC Okanagan Campus, Kelowna, Canada Professor Philip Ainslie, Ph.D. stated in the news release. “The potential benefits of this approach, but over the acute and more chronic time periods, in more middle-aged or elderly populations should now be prioritized. Establishing the impact of CBD delivery on the health of the circulatory systems, including the brain, could have major implications for the adjunct treatment of high blood pressure and some neurological diseases.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)